NIAID awards VaxInnate a $2.2M grant to develop dengue vaccine

04/5/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded VaxInnate a three-year grant worth $2.2 million to develop a recombinant tetravalent dengue vaccine using the company's Toll-like receptor (TLR) platform. The TLR technology is intended to increase vaccine efficacy and immunogenicity.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health